I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.AbbVie (NYSE: ABBV ) has been on a roll lately. The commercial business is humming, the p ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

CHINA - 2025/09/27: In this photo illustration, the AbbVie logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesAbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer’s agreement to lower its drug prices for Medicaid and a White House decision to grant a three-year exemption from 100% import tariffs. Since the market sees t ...

About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X ( ...

公司评级与目标价 - Leerink Partners维持对艾伯维公司的跑赢大盘评级 并将目标股价从210美元上调至243美元 [1] 核心业务表现 - 公司下一代免疫药物Skyrizi在已占据显著市场主导地位的情况下持续扩张 [2] - 公司下一代免疫药物Rinvoq和Skyrizi继续推动增长 [4] 营收增长预测 - 随着修美乐生物类似药带来的压力减小 公司总营收增长将加速 从2025年的8%上升至2026年的11% [3] 产品管线与里程碑 - 公司与仿制药达成和解 允许仿制版Rinvoq在2037年4月上市 比Leerink此前预测的晚了四年多 [1] - Leerink指出三个肿瘤学管线候选药物未来将对公司营收做出显著贡献 [3] 公司业务概况 - 艾伯维是一家生物制药公司 专注于为复杂和慢性疾病开发、生产和销售疗法 [4]

公司评级与股价表现 - 2025年10月1日 汇丰将艾伯维评级从买入下调至持有 股价为24439美元 [1] - 当前股价为24438美元 单日显著上涨555%或1284美元 [4] - 股价当日波动区间为232美元至24481美元 其中24481美元为过去一年最高价 [4] - 过去一年最低股价为16381美元 显示显著增长 [4] 公司运营与战略投资 - 公司启动位于马萨诸塞州伍斯特市的艾伯维生物研究中心7000万美元的扩建项目 [2] - 此次扩建是公司100亿美元美国业务投资的一部分 旨在增强生物制剂制造和研究能力 [2] - 扩建包括新建生产区域和一栋三层建筑 内含实验室、仓库和办公空间 [3] - 此举将实现部分肿瘤产品从欧洲向美国的转移 提升本土生产能力 [3] 财务状况与市场地位 - 公司当前市值约为4317亿美元 [4] - 当日交易量为1128万股 [4] - 公司是全球生物制药领域的关键参与者 专注于肿瘤学和免疫学创新药物研发 [1] - 战略投资对于公司在制药行业维持竞争优势至关重要 [3]

Key Points It's about to significantly expand its biologics research and manufacturing effort at a facility in Massachusetts. This should cost it a cool $70 million. 10 stocks we like better than AbbVie › The announcement of a new buildout, as well as developments on the political front, were the factors driving up AbbVie (NYSE: ABBV) stock on Wednesday. The pharmaceutical company's shares rose by nearly 6% in value as a result, during a session when the S&P 500 (SNPINDEX: ^GSPC) crept up a compara ...

AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Dividend Aristocrat Stocks to Invest in Right Now. AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability Photo by Dan Dennis on Unsplash AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that manufactures and markets innovative medicines. The demand for drugs is so stable that the industry is considered highly defensive, with little economic exposure. Even in recessions, doctors continue to prescribe treatments and patients cont ...

公司概况与市场地位 - 公司估值达到3940亿美元，收购艾尔建后成为顶级制药公司之一 [1] - 公司在关键治疗领域占据领导地位，包括免疫学、血液肿瘤学、神经科学、美学、眼科护理和女性健康 [3] - 公司拥有最受欢迎的癌症药物之一Imbruvica，以及新的免疫学药物Skyrizi和Rinvoq，为长期增长奠定良好基础 [2] 收购影响与产品组合 - 收购艾尔建改变了公司的产品组合，降低了对旗舰产品Humira的依赖 [1] - Humira被批准用于多种自身免疫性疾病，包括类风湿性关节炎、活动性银屑病关节炎、活动性强直性脊柱炎和克罗恩病 [1] 股价表现与技术指标 - 股价在9月30日的盘中交易中创下232.35美元的历史新高 [5] - 自7月10日趋势搜寻器发出新的“买入”信号以来，股价已上涨18.74% [4] - 股价拥有100%的Barchart“买入”观点，并且交易在关键移动平均线之上 [6] 增长前景与市场情绪 - 收购艾尔建后，公司凭借转型的产品组合和更高的长期增长前景脱颖而出 [6] - 分析师和投资者情绪积极，大多数主要公司给予“买入”或“强力买入”评级，目标价暗示有进一步上涨空间 [6]

Accessibility StatementSkip Navigation NORTH CHICAGO, Ill., Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass., which serves as a center of excellence for biologics research and development and manufacturing. This expansion is part of the company's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand criti ...